---
title: "Avalo Therapeutics, Inc. (AVTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AVTX.US.md"
symbol: "AVTX.US"
name: "Avalo Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:38:58.519Z"
locales:
  - [en](https://longbridge.com/en/quote/AVTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AVTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AVTX.US.md)
---

# Avalo Therapeutics, Inc. (AVTX.US)

## Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.avalotx.com](https://www.avalotx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: D (0.78)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 227 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -86.62% |  |
| Net Profit YoY | -216.06% |  |
| P/B Ratio | 11.60 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 792750567.52 |  |
| Revenue | 59000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -88.76% | E |
| Profit Margin | -143627.12% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -86.62% | E |
| Net Profit YoY | -216.06% | E |
| Total Assets YoY | -27.89% | E |
| Net Assets YoY | -44.28% | E |
| Cash Flow Margin | 70.44% | C |
| OCF YoY | -86.62% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 31.60% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Avalo Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-86.62%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-216.06%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "11.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "792750567.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "59000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-88.76%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-143627.12%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-86.62%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-216.06%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-27.89%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-44.28%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "70.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-86.62%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "31.60%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.36 | 444/386 | 0.98 | 0.72 | 0.65 |
| PB | 11.60 | 397/386 | 3.68 | 2.83 | 0.59 |
| PS (TTM) | 13436.45 | 307/386 | 1786.01 | 1350.85 | 165.24 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 85% |
| Overweight | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.27 |
| Highest Target | 52.00 |
| Lowest Target | 24.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AVTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AVTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AVTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AVTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**